As NICE celebrates its 25th anniversary, I thought I’d highlight one of the organisation’s most long-standing collaborative ...

Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123] Draft guidance Technology ...

Evidence from current practice provided by NHS England and analysed by NICE indicates that digital therapies recommended for PTSD could save over 5,000 hours of therapist time per 1,000 people. Almost ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Rucaparib is recommended, within its marketing authorisation, as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary ...

There is a simple discount patient access scheme for rucaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Suggested remit: To appraise the clinical and cost effectiveness of Itulazax 12 standardised quality pollen from white birch (betula verrucosa) sublingual lyophilisate immunotherapy (12 SQ-Bet SLIT) ...

The company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time.

Rucaparib (Rubraca) is available on the NHS. It is a possible maintenance treatment for relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by the lead team of committee A, which includes the chair and vice chair. Committee members ...